OBJECTIVE: To investigate the serologic response, predictors of response, and clinical outcomes associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and infection in ozanimod-treated participants with relapsing multiple sclerosis (RMS) from DAYBREAK. METHODS: DAYBREAK (ClinicalTrials.gov-NCT02576717), an open-label extension study of oral ozanimod 0.92 mg, enrolled participants aged 18-55 years with RMS who completed phase 1-3 ozanimod trials. Participants who were fully vaccinated against SARS-CoV-2 with mRNA or non-mRNA vaccines, were unvaccinated, and/or had COVID-19-related adverse events (AEs, with or without vaccination) and postvaccination serum samples were included (n = 288). Spike receptor binding domain (RBD) antibody levels (seroconversion: ≥0.8 U/mL) and serologic evidence of SARS-CoV-2 infection (nucleocapsid IgG: ≥1 U/mL) were assessed (Roche Elecsys/Cobas e411 platform). RESULTS: In fully vaccinated participants (n = 148), spike RBD antibody seroconversion occurred in 90% (n = 98/109) of those without serologic evidence of prior SARS-CoV-2 exposure (100% [n = 80/80] seroconversion after mRNA vaccination) and in 100% (n = 39/39) of participants with serologic evidence of viral exposure. mRNA vaccination predicted higher spike RBD antibody levels, whereas absolute lymphocyte count (ALC), age, body mass index, and sex did not. COVID-19-related AEs were reported in 10% (n = 15/148) of fully vaccinated participants-all were nonserious and not severe; all participants recovered. INTERPRETATION: Most ozanimod-treated participants with RMS mounted a serologic response to SARS-CoV-2 vaccination and infection, regardless of participant characteristics or ALC levels. In this analysis, all COVID-19-related AEs post-full vaccination in participants taking ozanimod were nonserious and not severe.

Brain and Mind Centre University of Sydney Sydney New South Wales Australia

Bristol Myers Squibb Princeton New Jersey USA

Department of Neurology Center for Neuroinflammation and Experimental Therapeutics Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA

Department of Neurology Medical Faculty Heinrich Heine University Düsseldorf Germany

Department of Neurology Medical University of Vienna Vienna Austria

Department of Neurology Weill Institute for Neurosciences University of California San Francisco San Francisco California USA

Palacký University Olomouc Olomouc Czech Republic

Zobrazit více v PubMed

Zeposia [package insert]. Bristol Myers Squibb; 2022.

Zeposia [summary of product characteristics]. Celgene Distribution B.V.; 2023.

Scott FL, Clemons B, Brooks J, et al. Ozanimod (RPC1063) is a potent sphingosine‐1‐phosphate receptor‐1 (S1P1) and receptor‐5 (S1P5) agonist with autoimmune disease‐modifying activity. Br J Pharmacol. 2016;173:1778‐1792. PubMed PMC

Harris S, Tran JQ, Southworth H, Spencer CM, Cree BAC, Zamvil SS. Effect of the sphingosine‐1‐phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS. Neurol Neuroimmunol Neuroinflamm. 2020;7:e839. PubMed PMC

Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS‐CoV‐2 assessed for up to 8 months after infection. Science. 2021;371:eabf4063. PubMed PMC

Bigaut K, Kremer L, Fabacher T, et al. Impact of disease‐modifying treatments of multiple sclerosis on anti‐SARS‐CoV‐2 antibodies: an observational study. Neurol Neuroimmunol Neuroinflamm. 2021;8:e1055. PubMed PMC

Bsteh G, Dürauer S, Assar H, et al. Humoral immune response after COVID‐19 in multiple sclerosis: a nation‐wide Austrian study. Mult Scler. 2021;27:2209‐2218. PubMed PMC

Achiron A, Mandel M, Dreyer‐Alster S, et al. Humoral immune response to COVID‐19 mRNA vaccine in patients with multiple sclerosis treated with high‐efficacy disease‐modifying therapies. Ther Adv Neurol Disord. 2021;14:17562864211012835. PubMed PMC

Wu X, Wang L, Shen L, Tang K. Response of COVID‐19 vaccination in multiple sclerosis patients following disease‐modifying therapies: a meta‐analysis. EBioMedicine. 2022;81:104102. PubMed PMC

Sormani MP, Inglese M, Schiavetti I, et al. Effect of SARS‐CoV‐2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine. 2021;72:103581. PubMed PMC

Apostolidis SA, Kakara M, Painter MM, et al. Cellular and humoral immune responses following SARS‐CoV‐2 mRNA vaccination in patients with multiple sclerosis on anti‐CD20 therapy. Nat Med. 2021;27:1990‐2001. PubMed PMC

Massetti GM, Jackson BR, Brooks JT, et al. Summary of guidance for minimizing the impact of COVID‐19 on individual persons, communities, and health care systems ‐ United States, august 2022. MMWR Morb Mortal Wkly Rep. 2022;71:1057‐1064. PubMed PMC

COVID‐19 Vaccines for People Who Are Moderately or Severely Immunocompromised. Centers for Disease Control and Prevention. 2022. Accessed October 11, 2022. https://www.cdc.gov/coronavirus/2019‐ncov/vaccines/recommendations/immuno.html?s_cid=11777:immunocompromised

Yamout BI, Zakaria M, Inshasi J, et al. MENACTRIMS practice guideline for COVID‐19 vaccination in patients with multiple sclerosis. Mult Scler Relat Disord. 2021;56:103225. PubMed PMC

Satyanarayan S, Safi N, Sorets T, et al. Differential antibody response to COVID‐19 vaccines across immunomodulatory therapies for multiple sclerosis. Mult Scler Relat Disord. 2022;62:103737. PubMed PMC

Cree BA, Selmaj KW, Steinman L, et al. Long‐term safety and efficacy of ozanimod in relapsing multiple sclerosis: up to 5 years of follow‐up in the DAYBREAK open‐label extension trial. Mult Scler. 2022;28:1944‐1962. PubMed PMC

Yazdani A, Mirmosayyeb O, Ghaffary EM, Hashemi MS, Ghajarzadeh M. COVID‐19 vaccines and patients with multiple sclerosis: willingness, unwillingness and hesitancy: a systematic review and meta‐analysis. Neurol Sci. 2022;43:4085‐4094. PubMed PMC

Cohen JA, Arnold DL, Comi G, et al. Safety and efficacy of the selective sphingosine 1‐phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo‐controlled, phase 2 trial. Lancet Neurol. 2016;15:373‐381. PubMed

Cohen JA, Comi G, Selmaj KW, et al. Safety and efficacy of ozanimod versus interferon beta‐1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24‐month, phase 3 trial. Lancet Neurol. 2019;18:1021‐1033. PubMed

Comi G, Kappos L, Selmaj KW, et al. Safety and efficacy of ozanimod versus interferon beta‐1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12‐month, phase 3 trial. Lancet Neurol. 2019;18:1009‐1020. PubMed

Gombolay GY, Dutt M, Tyor W. Immune responses to SARS‐CoV‐2 vaccination in multiple sclerosis: a systematic review/meta‐analysis. Ann Clin Transl Neurol. 2022;9:1321‐1331. PubMed PMC

Elecsys Anti‐SARS‐CoV‐2 S [product insert]. Roche Diagnostics GmbH; 2021.

Riester E, Findeisen P, Hegel JK, et al. Performance evaluation of the Roche Elecsys anti‐SARS‐CoV‐2 S immunoassay. J Virol Methods. 2021;297:114271. PubMed PMC

Jochum S, Kirste I, Hortsch S, et al. Clinical utility of Elecsys anti‐SARS‐CoV‐2 S assay in COVID‐19 vaccination: an exploratory analysis of the mRNA‐1273 phase 1 trial. Front Immunol. 2022;12:798117. PubMed PMC

Elecsys Anti‐SARS‐CoV‐2: Immunoassay for the Qualitative Detection of Antibodies Against SARS‐CoV‐2. Roche Diagnostics. 2020. Accessed October 11, 2022. https://diagnostics.roche.com/us/en/products/params/elecsys‐anti‐sars‐cov‐2.html

Carrat F, Villarroel PMS, Lapidus N, et al. Heterogeneous SARS‐CoV‐2 humoral response after COVID‐19 vaccination and/or infection in the general population. Sci Rep. 2022;12:8622. PubMed PMC

Le Bert N, Chia WN, Wan WY, et al. Widely heterogeneous humoral and cellular immunity after mild SARS‐CoV‐2 infection in a homogeneous population of healthy young men. Emerg Microbes Infect. 2021;10:2141‐2150. PubMed PMC

Cohen JA, Bermel RA, Grossman CI, et al. Immunoglobulin G immune response to SARS‐CoV‐2 vaccination in people living with multiple sclerosis within multiple sclerosis partners advancing technology and health solutions. Mult Scler. 2022;28:1131‐1137. PubMed PMC

Dreyer‐Alster S, Menascu S, Mandel M, et al. COVID‐19 vaccination in patients with multiple sclerosis: safety and humoral efficacy of the third booster dose. J Neurol Sci. 2022;434:120155. PubMed PMC

König M, Torgauten HM, Tran TT, et al. Immunogenicity and safety of a third SARS‐CoV‐2 vaccine dose in patients with multiple sclerosis and weak immune response after COVID‐19 vaccination. JAMA Neurol. 2022;79:307‐309. PubMed PMC

Meyer‐Arndt L, Braun J, Fauchere F, et al. SARS‐CoV‐2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod. J Neurol Neurosurg Psychiatry. 2022;93:960‐971. PubMed PMC

Milo R, Staun‐Ram E, Karussis D, et al. Humoral and cellular immune responses to SARS‐CoV‐2 mRNA vaccination in patients with multiple sclerosis: an Israeli multi‐center experience following 3 vaccine doses. Front Immunol. 2022;13:868915. PubMed PMC

Achtnichts L, Ovchinnikov A, Jakopp B, et al. SARS‐CoV‐2 mRNA vaccination in people with multiple sclerosis treated with fingolimod: protective humoral immune responses may develop after the preferred third shot. Vaccine. 2022;10:10. PubMed PMC

Drulovic J, Ivanovic J, Martinovic V, et al. Humoral response to SARS‐CoV‐2 COVID‐19 vaccines in patients with multiple sclerosis treated with immune reconstitution therapies. Mult Scler Relat Disord. 2021;54:103150. PubMed PMC

Achiron A, Mandel M, Gurevich M, et al. Immune response to the third COVID‐19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod. J Neurol. 2022;269:2286‐2292. PubMed PMC

Akgün K, Dunsche M, Katoul Al Rahbani G, et al. Different type and timing of S1P receptor modulator therapy impacts T and B cell response after SARS‐CoV2 vaccination [abstract P316]. Mult Scler. 2022;28(3 suppl):347‐348.

Kantor D. SARS‐CoV‐2 vaccine response in RMS patients treated with ozanimod and other DMTs [abstract P13‐4.008]. Neurology. 2022;98(18 suppl):3849.

Baker D, Forte E, Pryce G, et al. The impact of sphinogosine‐1‐phosphate receptor modulators on COVID‐19 and SARS‐CoV‐2 vaccination. Mult Scler Relat Disord. 2022;69:104425. PubMed PMC

Jakimovski D, Zakalik K, Awan S, et al. COVID‐19 vaccination in multiple sclerosis and inflammatory diseases: effects from disease‐modifying therapy, long‐term seroprevalence and breakthrough infections. Vaccine. 2022;10:695. PubMed PMC

Peluso MJ, Takahashi S, Hakim J, et al. SARS‐CoV‐2 antibody magnitude and detectability are driven by disease severity, timing, and assay. Sci Adv. 2021;7:eabh3409. PubMed PMC

Zobrazit více v PubMed

ClinicalTrials.gov
NCT02576717